The results of the TOPGEAR trial on gastric and GEJ adenocarcinoma – EORTC

EORTC (European Organisation for Research and Treatment of Cancer) shared a post on LinkedIn:

”We’re thrilled to announce the results of the TOPGEAR trial on gastric and gastroesophageal junction adenocarcinoma.

The study showed that the addition of preoperative chemoradiotherapy did not improve progression-free survival or overall survival compared to perioperative chemotherapy alone.

This breakthrough will impact clinical practice worldwide.

Learn more here.”

Source: EORTC/LinkedIn